Efficacy and safety of primary percutaneous trans-axillary artery transcatheter aortic valve replacement for severe aortic stenosis - Primary trans-axillary artery access TAVR for AS

Shonan Kamakura General Hospital0 sites25 target enrollmentMay 20, 2022

Overview

No summary available.

Registry

who.int

Start Date

May 20, 2022

End Date

October 30, 2025

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\) contraindication for bioprosthesis implantation 2\) Contraindication for following medicine aspirine, ticlopidine, heparine or contrast medium 3\) active endocarditis or sepsis 4\) Left ventricular thrombus 5\) decompensated heart failure with NYHA4 symptom 6\) Cardiogenic shock with hemodynamic mechanical support 7\) Post coronary artery graft bypass using ipsilateral internal mammary artery 8\) Post pacemaker implantation at ipsilateral axillary vein 9\) coronary artery disease with Indication for coronary artery bypass graft surgery 10\) Indication for surgical valvular treatment 11\) Blood disease: WBC\<1000mm3,Plt\<50000cellc/mm3 12\) Severe dementia 13\) Life\-expectancy\<1year due to other than heart disease 14\) pregnancy or breast\-feed 15\) access artery diameter\<5mm by CT or echo 16\) severe calcification or tortuosity of access 17\) inhibitive anatomy for trans femoral access 18\) Aorto\-subclavian angle\>90degree 19\) Subclavian artery originated from distal aortic arch